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noAIF 42%AIF). Overall, with each subsequent line of therapy the proportion of AIF
patients taking fulvestrant increased. In addition, of those with AIF, 35% (n905)
switched to chemotherapy prior to study end. CONCLUSIONS: The majority of
ER/HER2-metastatic breast cancer patients treatedwith AIs will fail at least 1 line
of therapy. Prior AI treatment did not appear associated with future AI failure.
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DTIC AND GM-CSF IN THE TREATMENT OF PATIENTS WITH METASTATIC
MELANOMA
Zhao Z, Wang S, Barber B, Wagner V
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OBJECTIVES: To describe patients with metastatic melanoma being treated with
mono-therapy, dacarbazine (DTIC) or granulocyte-macrophage colony-stimulating
factor (GM-CSF). METHODS: Using a large US medical claims database, patients
were identified between 2005 and 2010 using 2 melanoma diagnoses (ICD-9-CM:
172.xx, V10.82) and 2 diagnoses for metastasis (ICD-9-CM: 197.xx, 198.xx). Pa-
tients who received mono-therapy with DTIC or GM-CSF as the first documented
drug therapy after metastatic diagnosis were identified. Patient demographic and
clinical characteristics and treatment duration were compared between patients
treated with DTIC and those who received GM-CSF. Furthermore, comparisons
were also made between the two treatment groups after 1-to-1 matching on age,
gender, and baseline comorbidities. RESULTS: A total of 81 patients with meta-
static melanoma receiving first-line DTIC and 24 patients with metastatic mela-
noma receiving first-line GM-CSF were included in this analysis. On average, DTIC
patients were 8.5 years older (p  0.009) and had higher baseline Charlson Comor-
bidity Index scores (D0.43, p  0.005) than GM-CSF patients. The mean duration of
first line treatment was 94 days on DTIC and 135 days on GM-CSF. Themean length
of follow-up from the start of first line was 257 days on DTIC and 451 days on
GM-CSF. After each GM-CSF patient was matched with a DTIC patient on age,
gender, and baseline Charlson Comorbidity Index score, the mean duration of first
line treatment was 79 days on matched DTIC and 135 days on GM-CSF, and the
mean length of follow-up from the start of first line was 317 days onmatched DTIC
and 451 days on GM-CSF. CONCLUSIONS: Patients withmetastatic melanomawho
received DTIC treatment were older and had higher comorbidity index scores but
shorter treatment duration than those who received GM-CSF; the difference in
treatment duration remained after DTIC patients were matched with GM-CSF pa-
tients on age, gender and comorbidity index scores.
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OBJECTIVES: Lapatinib is an oral dual tyrosine kinase inhibitor that has been
shown to improve time to progression when combined with capecitabine versus
capecitabine monotherapy in women with HER2 MBC previously treated with
trastuzumab. Data on health care utilization and costs among women receiving
lapatinib in typical clinical practice are scarce. METHODS: This was retrospective
observational descriptive study of health care utilization and costs among women
receiving lapatinib after treatment with trastuzumab for MBC in the Thomson
MedStatMarketScan Commercial andMedicare health insurance claims databases
(1/2000-3/2010). Monthly utilization and costs were calculated for the 12 months
prior to initiation of lapatinib (pre-treatment period), the lapatinib treatment pe-
riod, and the post-treatment period (end of lapatinib treatment to end of
study/disenrollment). RESULTS: Mean (SD) age was 52(8) and 72(6) years in Com-
mercial (n572) andMedicare (n94) patients respectively. Lapatinib was initiated
in combination w/capecitabine in 63% and w/trastuzumab in 22% of patients. Me-
dian time to lapatinib discontinuation was 7.4 months. The mean(SD) number of
visits/month declined from 6.1(3.0) during pre-treatment to 5.5(3.5) during treat-
ment, and to 4.6(3.9) during post-treatment. The mean(SD) number of inpatient
days/month increased progressively from 0.24(0.52) during pre-treatment, to
0.53(1.39) during treatment and 0.96(2.52) post-treatment. Mean(SD) lapatinib
costs/month during treatment were $2,097($877). Mean(SD) trastuzumab costs/
month were $2,762($2,020), $722($1,731), and $1,166($2,134) during pre-treatment,
treatment, and post-treatment, respectively. Correspondingmean(SD) chemother-
apy costs/month were $1,355($1,898), $1,496($1,698), and $1,437($2,729), respec-
tively, while corresponding mean(SD) chemotherapy administration costs/month
were $508($477), $189($289), and $326($516) respectively.Mean(SD) other (including
inpatient) costs/month were $5,446($4,680), $5,564($7,198), and $6,880($9,726), re-
spectively. Mean(SD) total costs/month were $10,071($6,056), $10,067($7,695), and
$9,809($10,853), respectively. CONCLUSIONS: In this sample of women receiving
lapatinib after treatment with trastuzumab for MBC, monthly health care costs
were similar during lapatinib treatment versus prior to treatment, despite progres-
sively increasing inpatient utilization and costs, potentially reflecting disease pro-
gression over time.
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OBJECTIVES: Iron deficiency anemia is commonly treated with intravenous (IV)
iron in oncology, especially in combination with erythropoiesis-stimulating
agents. Central venous access port – PortaCath (PAC) – is used to provide long-term
venous access and to deliver chemotherapy in this setting. There is a lack of data,
however, on the use of PAC for the administration of IV iron in cancer patients. The
aim of this survey was to assess the frequency of this practice, and the reasons
supporting it.METHODS: FERPAC was a declarative survey conducted in France. A
total of 497 oncologists/hematologists were interviewed on their practices regard-
ing their use of IV iron. Answers were collected and registered into a central-based
server. RESULTS: A total of 141 questionnaires were collected. Most used IV irons
were iron sucrose and ferric carboxymaltose, for which respectively 77.4% and
77.6% of physicians reported to use the PAC for the administration. The main
reasons for using the PAC were the easy way of administration (28.2%) and the
preservation of patient venous capital (26.1%), given that efficacy and safety were
expected to be at least acceptable or even as good as peripheral administration. IV
iron administration was planned strictly after chemotherapy (45.7%), strictly be-
fore (37.2%), or without any preference (17.0%). Reasons for not using the PACwere
either a history of thrombosis (45.1%) or potential drug-drug interactions (17.7%).
CONCLUSIONS: IV irons are currently commonly administered through the PAC in
cancer patients in France. Further studies are needed to confirm the efficacy and
safety of the administration of IV iron through PAC.
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OBJECTIVES: To determine the utilization and predictors of Cyclophosphamide-
Methotrexate-Fluorouracil (CMF) chemotherapy in women with early stage breast
cancer.METHODS:A longitudinal studywas conducted including patients 66 years
and above, diagnosed with stage I-III breast cancer using SEER cancer registry data
linkedwithMedicare claims. Patientswere divided into two groups as those receiv-
ing CMF chemotherapy and those receiving other chemotherapy. A patient was
considered as receiving CMF chemotherapy if she started chemotherapywithin six
months and had a claim of Cyclophosphamide, Methotrexate and 5-Fluorouracil
within one year of diagnosis. Multiple logistic regression was conducted to assess
the predictors of CMF chemotherapy use. RESULTS: A total of 11,322 women re-
ceived chemotherapy within the first six months and 24.4% of these (n  2758)
received CMF chemotherapy. A patient had 2.3 times greater odds of receiving CMF
chemotherapy with each year increase in age. Patients who received a lymph node
dissection had 1.4 times greater odds of receiving CMF chemotherapy than patients
who did not receive it. Patients with stage II tumor had 1.5 times greater odds of
receiving CMF chemotherapy than stage I patients. CMF use decreased by 23%with
estrogen receptor positivity and 18% when radiation was administered to the pa-
tient. Patients with Charlson’s comorbidity index  1 were 16% more likely to
receive CMF chemotherapy than patients who had a Charlson’s comorbidity score
of 0. CMF use decreased overall with time. CONCLUSIONS: This study found that
age, comorbidity index, estrogen receptor status, radiation and lymph node dissec-
tion were significant predictors of CMF chemotherapy. The use of CMF chemother-
apy increased with age, comorbidity index and lymph node dissection and de-
creased with estrogen receptor positivity and irradiation. The declining time trend
in the use of CMF chemotherapy probably indicates the increased use of newer
chemotherapy regimens like the Anthracycline and Taxane based regimens.
PCN126
RADIATION AFTER BREAST-CONSERVING SURGERY: COMPLIANCE OF CLINICAL
GUIDELINE AMONG YOUNG WOMEN WITH EMPLOYMENT-BASED INSURANCE
IN THE UNITED STATES
Pan IW1, Smith BD2, Shih YCT1
1The University of Chicago, Chicago, IL, USA, 2The University of Texas MD Anderson Cancer
Center, Houston, TX, USA
OBJECTIVES: Evidences-based literature has confirmed the effectiveness of radia-
tion therapy (RT) following breast conserving surgery (BCS); thus several practice
guidelines recommend RT after BCS. This study explored factors associated guide-
line compliance among young women with insurance because compliance in this
population is not well-understood. METHODS: Using the 2004-2009 MarketScan®
Research Database, we identified our study cohort as women who had a BCS be-
tween July 1, 2004 and December 31, 2008, and had continuous enrollment from 6
months before to 12 months after the date of BCS. We excluded patients who had
mastectomy within 3 months of BCS. We used Pearson Chi-Squared test and mul-
tivariate logistic regression to ascertain factors associated the receipt of RT within
one year of BCS. We performed Hosmer-Lemeshow goodness-of-fit and other
model diagnostic tests to determine the finalmodel specification and conducted all
analyses using SAS® 9.2 and Stata® 11.0 software. RESULTS: A total of 20,756 of the
24,011 (86.44%) BCS patients received RTwithin a year of their surgery. Results from
the logistic regression showed that the odds of RT increased with age, compared
with patients under 40, the odds ratio was 1.63 (95% confidence interval: 1.40-1.90),
1.86 (1.61-2.16), and 2.04 (1.73-2.39) for those in 40-49, 50-59, and  60 age group,
respectively. Patients who did not enroll in HMOs (1.27; 1.17-1.37) and was primary
insurance policy holder (1.31; 1.21-1.41)were significantlymore likely to receive RT.
Comparewith patients resided in the Northeast region, those in theWest were less
likely to receive RT (0.71; 0.62-0.82). Positive association with hospital density was
also observed (1.17; 1.04-1.31). CONCLUSIONS: Although the compliance rate
among young women with employment-based insurance was higher than that
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